Fresenius Medical Care AG (NYSE:FMS) Receives Consensus Rating of "Hold" from Analysts

Shares of Fresenius Medical Care AG (NYSE:FMS - Get Free Report) have been given an average rating of "Hold" by the eight analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $24.00.

A number of research analysts have recently weighed in on the company. StockNews.com lowered Fresenius Medical Care from a "strong-buy" rating to a "buy" rating in a report on Friday. Morgan Stanley lowered Fresenius Medical Care from an "equal weight" rating to an "underweight" rating in a report on Monday, January 8th.

Fresenius Medical Care Stock Up 1.8 %

NYSE:FMS traded up $0.34 on Tuesday, hitting $19.24. The stock had a trading volume of 216,053 shares, compared to its average volume of 434,479. The business's fifty day moving average is $19.61 and its 200 day moving average is $19.59. The company has a market cap of $11.29 billion, a PE ratio of 20.91, a P/E/G ratio of 0.90 and a beta of 1.00. The company has a quick ratio of 1.07, a current ratio of 1.42 and a debt-to-equity ratio of 0.47. Fresenius Medical Care has a 52 week low of $16.37 and a 52 week high of $27.72.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.11. The business had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.32 billion. Fresenius Medical Care had a return on equity of 4.99% and a net margin of 2.56%. On average, equities research analysts expect that Fresenius Medical Care will post 1.53 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care

A number of hedge funds have recently bought and sold shares of the business. Clear Street Markets LLC purchased a new stake in Fresenius Medical Care in the fourth quarter worth $28,000. Bruce G. Allen Investments LLC purchased a new stake in Fresenius Medical Care in the fourth quarter worth $31,000. Hartford Financial Management Inc. grew its position in shares of Fresenius Medical Care by 98.8% in the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company's stock valued at $35,000 after purchasing an additional 839 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Fresenius Medical Care by 349.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company's stock valued at $48,000 after purchasing an additional 1,799 shares in the last quarter. Finally, Atlas Capital Advisors LLC purchased a new position in shares of Fresenius Medical Care in the fourth quarter valued at $55,000. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.